Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Senior Vice President | February 27, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 27, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 39,164 |
Ending reported balance
After 2026-03-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-27 · Tax withholding · Disposed 1,384 · Balance 39,873 Row 2 · 2026-03-02 · Sale · Disposed 709 · Balance 39,164 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 01:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 709 | $115.58 | $81,946.22 |
DisclosureSEC source: 0002058129-26-000007 · form4-03042026_010300.xml · nonDerivative · entry 2 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,164 Read SEC document |
| February 27, 2026 Filed Mar 4, 2026 01:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,384 | $116.26 | $160,903.84 |
DisclosureSEC source: 0002058129-26-000007 · form4-03042026_010300.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,873 Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 44,821 | $0.00 Strike: $114.60 | $0.00 |
DisclosureSEC source: 0002058129-26-000002 · form4-02272026_120249.xml · derivative · entry 2 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,821 Underlying: Common Shares · 44,821 shares Expires 2036-02-23 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,940 on February 24, 2027, 14,940 on February 24, 2028, and 14,941 on February 24, 2029. Read SEC document |
| February 24, 2026 Filed Feb 27, 2026 00:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,873 | $0.00 | $0.00 |
DisclosureSEC source: 0002058129-26-000002 · form4-02272026_120249.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,257 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| November 25, 2025 Filed Nov 25, 2025 21:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,586 | $128.02 | $203,042.57 |
DisclosureSEC source: 0002058129-25-000009 · form4-11252025_091124.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,384 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.02 to $128.06, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 562 | $138.17 | $77,651.54 |
DisclosureSEC source: 0001415889-25-006794 · form4-03052025_010316.xml · nonDerivative · entry 1 Shroff Eric · CIK 0002058129 · Senior Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,970 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.